Skip to content


at the edge of impossible

OXGENE’s novel mammalian antibody display technology targets challenging membrane proteins and facilitates downstream antibody manufacturing.

Design and Discover

Mammalian display and optimized expression systems facilitate antibody discovery against intractable targets.

Develop and Manufacture

Automated expression platform enables rapid, small-scale antibody production and characterization. Licensable CHO-based SSI cell lines for antibody validation.

Antibody at the edge of impossible

Our proprietary mammalian antibody discovery platform and custom antibody libraries break new ground in the identification of novel antibodies against challenging membrane proteins. We also offer a bioinformatics-led approach to humanise existing antibodies, and our industry leading SnapFast™ plasmid technology facilitates subsequent antibody engineering and production steps.

We offer an integration solution that supports your entire antibody discovery, engineering and characterization workflow.


Mammalian Display

OXGENE has developed a novel CHO-based mammalian display antibody technology targeting membrane proteins. We construct and routinely screen synthetic antibody libraries above 10⁹ variants, up to 100-fold higher than typical mammalian display techniques. We achieve our large library size by the innovative packaging of antibody libraries into viral particles, which we then use to infect CHO cells with 90% integration efficiency.

We use this cutting-edge method to discover novel binders and generate therapeutic leads. We can also apply this method to affinity maturation projects.

These major advantages complement other key features, including presentation of the proteins in their native configuration – including correct glycosylation - to avoid the need for downstream antibody purification or humanisation. We also use the CHO cell line to accelerate the development of identified antibodies as biotherapeutics. 


Antibody Humanization

OXGENE applies bioinformatics-led antibody humanisation to find the closest possible human-to-animal match. Our in-house algorithms employ pattern recognition and machine learning to identify optimal matches.

We then use our proprietary MHC class II binding prediction software to perform immunogenicity risk analysis to shortlist preferred antibody candidates for subsequent characterisation. Finally, key risk factors affecting antibody function or manufacturability are identified and excluded from shortlisted candidates.

Variants generated following in-silico analysis are expressed using OXGENEs high-yielding in-house expression plasmids (including constant region panel) and HEK293 or CHO-based suspension cell lines. Proteins are purified by PrA chromatography before affinity characterisation (SPR/competition ELISA). 

Work with us at the edge of impossible

Job Opportunities

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.


Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of qualify control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.